USFDA inspection at Indoco Remedies Limited's Solid Oral Formulation Facility - Plant 1 at Goa

The United States Food and Drug Administration (USFDA) has conducted GMP inspection of the Solid Oral Formulation Facility (Plant 1) at Goa. The inspection was conducted from 16th January, 2023 to 20th January 2023.

The USFDA has issued Form 483 with 9 observations, which will be addressed within stipulated time. We believe that this will not have an impact on the supplies and the existing revenues from this facility.

The Company is committed to maintain compliances across all our facilities with cGMP quality standards at all times.

Shares of Indoco Remedies Limited was last trading in BSE at Rs. 391.25 as compared to the previous close of Rs. 394.20. The total number of shares traded during the day was 2725 in over 215 trades.

The stock hit an intraday high of Rs. 394.75 and intraday low of 390.85. The net turnover during the day was Rs. 1069450.00.

Source : Equity Bulls

Keywords

IndocoRemedies INE873D01024 USFDA Inspection Form483 9Observations SolidOralFormulationFacility Goa